.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have recently identified ZFP91 as a critical ZFP91 myeloid leukemia regulator that drives EVI1 expression. Historically, clinicians linked EVI1 overexpression primarily to 3q26 chromosomal rearrangements. However, this study reveals how EVI1 levels remain high in many patients even without these specific genetic abnormalities. Consequently, these findings offer a fresh biological explanation for the poor clinical outcomes observed in a broader range of myeloid leukemia cases.
Ecotropic viral integration site 1 (EVI1) is a transcription factor that maintains hematopoietic stem cell function. Unfortunately, it becomes highly oncogenic when overexpressed in myeloid cells. While chromosomal rearrangements typically cause this elevation, many leukemia cases display high EVI1 levels despite possessing a normal 3q26 locus. To solve this clinical mystery, researchers utilized genome-wide CRISPR screening. They successfully discovered that zinc finger protein 91 (ZFP91) acts as the primary activator of EVI1 in these contexts.
Mechanistically, ZFP91 binds directly to the EVI1 promoter region. This binding actively enhances crucial histone modifications, specifically H3K4me3 and H3K27ac. Additionally, it significantly increases chromatin accessibility, which facilitates aggressive gene transcription. Furthermore, the study demonstrated that knocking out ZFP91 effectively reduced leukemia cell proliferation and EVI1 expression levels. Therefore, the ZFP91-EVI1 axis represents a promising new therapeutic target for patients facing EVI1-positive myeloid malignancies.
EVI1 is essential for maintaining hematopoietic stem cells, but its aberrant overexpression is a major indicator of poor prognosis and therapy resistance in myeloid leukemia.
ZFP91 acts as a transcriptional activator that binds to the EVI1 promoter, enhancing active chromatin marks like H3K4me3 and H3K27ac to drive gene expression.
The identification of the ZFP91-EVI1 axis suggests that ZFP91 could be a target for future therapies, especially for patients who overexpress EVI1 without traditional chromosomal rearrangements.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Hayashida H et al. Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia. Oncogene. 2026 Apr 25. doi: 10.1038/s41388-026-03727-7. PMID: 42034869.
Unoki M et al. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 2003 Jun;22(6):1213-9. PMID: 12738987.
Glass C et al. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. PLoS ONE. 2013;8(6):e67134. doi: 10.1371/journal.pone.0067134.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers identify ZFP91 as a master regulator of EVI1 expression in myeloid leukemia, explaining high EVI1 levels in cases without 3q26 abnormalities....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
